IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
AbstractAim:To investigate whether the insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs1470579 and rs4402960 polymorphisms are associated with the development of type 2 diabetes mellitus (T2DM) and the repaglinide therapeutic efficacy in Chinese T2DM patients.Methods:A case-control study of a total of 350 patients with T2DM and 207 healthy volunteers was conducted to identify their genotypes for the IGF2BP2 rs1470579 and rs4402960 polymorphisms using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Forty-two patients were randomly selected to undergo an 8-week repaglinide treatment (3 mg/d). Fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin (HbAlc), fasting serum insulin (FINS), postprandial serum insulin (PINS), homeostasis model assessment for insulin resistance (HOMA-IR), serum triglyceride, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), and high-density lipoprotein-cholesterol (HDL-c) were determined before and after repaglinide treatment.Results:The frequencies of the IGF2BP2 rs1470579 C allele and the rs4402960 T allele were higher in T2DM patients than in healthy controls (P<0.05 and P<0.001, respectively). The effects of the repaglinide treatment on FPG (P<0.05) and PPG (P<0.05) were reduced in patients with the rs1470579 AC+CC genotypes compared with AA genotype carriers. Patients with the rs4402960 GT+TT genotypes exhibited an enhanced effect of repaglinide treatment on PINS (P<0.01) compared with GG genotype subjects.Conclusion:The IGF2BP2 rs1470579 and rs4402960 polymorphisms may be associated with the development of T2DM, and these polymorphisms may affect the therapeutic efficacy of repaglinide in Chinese T2DM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Replication of Genome-Wide Association Signals in UK Samples Reveals Risk Loci for Type 2 Diabetes
Zeggini, E., Weedon, M. N., Lindgren, C. M., Frayling, T. M., Elliott, K. S., Lango, H., Timpson, N. J., Perry, J. R. B., Rayner, N. W., Freathy, R. M., et al. (2007) · Science · doi:10.1126/science.1142364 · Cited by 2,194
Wellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Nielsen, J., Christiansen, J., Lykke-Andersen, J., Johnsen, A. H., Wewer, U. M., & Nielsen, F. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1262 · Cited by 721
Ng, M. C. Y., Park, K. S., Oh, B., Tam, C. H. T., Cho, Y. M., Shin, H. D., Lam, V. K. L., Ma, R. C. W., So, W. Y., Cho, Y. S., et al. (2008) · Diabetes · doi:10.2337/db07-1583 · Cited by 362
Wu, Y., Li, H., Loos, R. J. F., Yu, Z., Ye, X., Chen, L., Pan, A., Hu, F. B., & Lin, X. (2008) · Diabetes · doi:10.2337/db08-0047 · Cited by 240
Cited by
Ali, O. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i4.114 · Cited by 350
Rao, P., Wang, H., Fang, H., Gao, Q., Zhang, J., Song, M., Zhou, Y., Wang, Y., & Wang, W. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060574 · Cited by 61
“In addition, some studies showed an association of the IGF2BP2 variant with T2DM under the recessive model [26,40], while others found the under the dominant genetic model [27,34,37,51,56].”
Wu, X., Lu, R., Wang, L., Wang, Y., Dai, Y., Wang, C., Yang, Y., Guo, F., Xue, J., & Yang, D. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27079 · Cited by 40
“In addition, insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2), also known as IMP‐2, was a messenger RNA (mRNA)‐binding protein, which displayed the effect of RNA localization, stability, and translation, and overexpressed in human organs, such as fetal lung, kidney, thymus, and pancreatic islets.(12,13) I…”
Background
Metadata
- Authors
- Huang, Q., Yin, J.-Y., Dai, X.-P., Pei, Q., Dong, M., Zhou, Z.-G., Huang, X., Yu, M., Zhou, H.-H., & Liu, Z.-Q.
- Venue
- Acta Pharmacologica Sinica
- Published
- 2010-06
- Volume
- 31
- Issue
- 6
- Pages
- 709-717
- ISSN
- 0253-9756 (ISSN-L)
- 1671-4083
- 1745-7254
- OpenAlex
- W2092370356
- Cited by
- 66
- References
- 8
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population. https://app.cochat.ai/papers/10.1038/aps.2010.47
- The paper
- Huang, Q., Yin, J.-Y., Dai, X.-P., Pei, Q., Dong, M., Zhou, Z.-G., Huang, X., Yu, M., Zhou, H.-H., & Liu, Z.-Q. (2010). IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population. Acta Pharmacologica Sinica. https://doi.org/10.1038/aps.2010.47
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.